Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,407 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cardiovascular Function Clear all

Conditions: Peripheral Arterial Disease, Peripheral Artery Disease
Interventions: MitoQ; Dietary Supplement
Lead sponsor: University of Nebraska; Other
Eligibility: 50 Years to 85 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Atherosclerosis, Healthy, Hypertension
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Myocardial Infarction, Coronary Artery Disease
Interventions: Physiology-guided NCL PCI, Angiography-guided NCL PCI; Procedure
Lead sponsor: Population Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 5,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Wichita, Kansas + 10 more

Conditions: Heart Defects, Congenital, Hypoplastic Left Heart Syndrome, Single Ventricle Defect, Stress, Psychological
Interventions: Early palliative care team consultation; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hematologic Disease, Hemophilia A
Interventions: Kogenate (BAY14-2222); Drug
Lead sponsor: Bayer; Industry
Eligibility: 30 Years to 45 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: Aurora, Colorado • Chapel Hill, North Carolina • Houston, Texas

Conditions: Type 2 Diabetes
Interventions: Montelukast, Montelukast Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 14 Years to 24 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hypertension, Left Ventricular Hypertrophy, Left Ventricular Dysfunction, Left Atrial Dilatation, Left Ventricular Diastolic Dysfunction, Kidney Diseases, Kidney Injury, Kidney Dysfunction, Sodium Urine High, Blood Pressure Disorders, Uric Acid Retention, Angiotensin Hypertension, Autonomic Dysfunction, Autonomic Imbalance, Pediatric Kidney Disease, Pediatric Obesity, Proteinuria, Albuminuria
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 7 Years to 18 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Coronary Artery Disease, Ischemic Heart Disease
Interventions: Philips SyncVision system with Philips pressure wires, standard of care angiographically-guided PCI; Device · Procedure
Lead sponsor: Philips Clinical & Medical Affairs Global; Industry
Eligibility: 18 Years and older
Enrollment: 3,212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 40
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 35 more

Conditions: Heart Disease
Interventions: cardiovascular MRI (CMR), Conventional Cardiologic Evaluation; Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 7 Years to 95 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Stroke
Interventions: Arm training in standing; Behavioral
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Atherosclerosis, Hypercholesterolemia
Interventions: fasudil; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Hypertension, Valvular Heart Disease, Congenital Heart Disease, Congestive Heart Failure, Pulmonary Embolism, Acute Coronary Syndrome
Interventions: Measuring Right Ventricular Size and Function; Diagnostic Test
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Hypertension, Left Ventricular Hypertrophy
Interventions: Eplerenone, Chlorthalidone, Potassium; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lymphedema, Lymphatic Disorders, Lipedema, Vascular Malformation, Vascular Anomaly, Dercum Disease
Interventions: NIRFLI with ICG; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 3 Months and older
Enrollment: 283 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2030
U.S. locations: 3
States / cities: Houston, Texas • The Woodlands, Texas

Conditions: Depression, HIV
Interventions: Beating the Blues; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Chuvash Polycythemia, Cerebrovascular Disease, Pulmonary Hypertension, Sickle Cell Anemia
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 3 Years to 20 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2014
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Bethesda, Maryland + 2 more

Conditions: Coronary Artery Disease, Atherosclerosis, Inflammation, Endothelial Dysfunction
Interventions: Rilonacept, Placebo; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Stroke, Hemiparesis, Pre-Hypertension, Hypertension
Interventions: Low-Frequency Passive Vibration, High-Frequency Pasive Vibration; Other
Lead sponsor: Florida State University; Other
Eligibility: 40 Years to 80 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Exercise, Cardiovascular Function, Fatigue, Muscular Power
Interventions: inertial-load exercise (ILE); Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 40 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Cardiovascular Disease, Inflammation
Interventions: Controlled feeding diet; Other
Lead sponsor: Penn State University; Other
Eligibility: 30 Years to 75 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Hypertension
Interventions: amlodipine and olmesartan, losartan and HCTZ; Drug
Lead sponsor: InVasc Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Tucker, Georgia

Conditions: Left Ventricular Diastolic Dysfunction
Interventions: BNP (nesiritide), Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Type 2 Diabetes, Heart Failure, Reduced Ejection Fraction
Interventions: Ketone Monoester (KE); Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Cardiovascular Disease
Interventions: ALT-711 (alagebrium chloride); Drug
Lead sponsor: Synvista Therapeutics, Inc; Industry
Eligibility: 50 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients

Racial Differences in Control of Blood Vessel Tone and Blood Flow

Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

Impact of Early Intervention on Maternal Stress in Mothers of Fetuses Diagnosed With Single Ventricle Physiology

BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)

SMART 2D: Study of Montelukast's Effects on Renal and Cardiovascular Health in Adolescents and Young Adults With Type 2 Diabetes

Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)

Distal Evaluation of Functional Performance with Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting

Evaluation of Cardiac Function With Cardio-respiratory Synchronized MRI

Arm Training in Standing After Stroke

The Effect of Fasudil on Vascular Function in Humans

Evaluating Right Ventricular (RV) Size and Function Using the Upper Valley RV Algorithm and Novel Imaging Modalities

Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension

Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders

Depression Therapy to Improve Cardiovascular Risk in HIV

Pulmonary Hypertension, Hypoxia and Sickle Cell Disease

Rilonacept to Improve Artery Function in Patients With Atherosclerosis

The Acute Effects of Passive Vibration on Cardiovascular Function in Individuals With Stroke

Physiological Responses to Maximal 4-s Sprint Interval Cycling

Effect of a Spice Blend on Cardiovascular Risk Factors and Diet Satisfaction

Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome

Human Brain Natriuretic Peptide (BNP) (or Nesiritide) to Help Heart, Kidney and Humoral Function.

Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes

The STRETCH Study: Distensibility on Endothelial-Dependent Vasoreactivity in Subjects With Systolic Hypertension